Andre the Giant and Acromegaly: What History and Medicine Tell Us About His Condition

Who Was Andre the Giant and What Condition Did He Have?

Andre Rene Roussimoff was born on May 19, 1946, in Coulommiers, France. His extraordinary size was apparent by adolescence and stemmed from acromegaly, a condition in which a benign pituitary adenoma secretes excess growth hormone continuously after the epiphyseal plates have fused. The result is progressive enlargement of soft tissue, bone, and visceral organs rather than simple linear height gain.

Acromegaly affects approximately 3 to 4 people per million per year, with a prevalence of roughly 40 to 60 cases per million population 1. Because symptoms develop slowly, the average delay from symptom onset to diagnosis is 4 to 10 years 2. Andre's condition was almost certainly active from childhood or early adolescence, given the gigantism-like linear growth he demonstrated before skeletal maturity.

Gigantism vs. Acromegaly: Why the Distinction Matters

When GH excess begins before epiphyseal fusion, the clinical picture is gigantism. After plates fuse, acromegaly dominates. Andre almost certainly experienced a hybrid course: initial gigantism driving his remarkable stature, followed by acromegaly producing the progressive soft-tissue and visceral changes visible across his career photographs from the 1970s through the early 1990s.

Untreated GH excess raises IGF-1 continuously. Elevated IGF-1 drives cardiac hypertrophy, insulin resistance, sleep apnea, arthropathy, and colon polyp formation. The Endocrine Society's 2014 guideline states directly: "Patients with active acromegaly have increased cardiovascular morbidity and mortality" 3.

The Pituitary Adenoma Underlying His Condition

Pituitary somatotroph adenomas account for approximately 10 percent of all pituitary tumors 4. Most are macroadenomas (diameter >10 mm) at diagnosis, particularly when diagnosis is delayed. Macroadenomas can compress the optic chiasm, produce hypopituitarism, and, if invasive, become technically difficult to resect completely. Andre's visible coarsening of facial features, prognathism, and hand and foot enlargement are textbook presentations of a large, long-standing somatotroph adenoma.

What Did Andre the Giant Say About His Medical Condition?

Andre gave relatively few detailed public statements about his health. He was famously private about the medical dimensions of his fame. The clearest documented account comes from a 1981 interview with sports journalist Bill Apter, in which Andre acknowledged he had a "glandular problem" but declined to elaborate on treatment. He did not use the clinical term acromegaly publicly.

His friend and fellow wrestler Ric Flair stated in a 2019 podcast interview on Ric Flair's podcast "Wooooo Nation Uncensored" that Andre "knew what he had, he knew it would shorten his life, and he chose not to deal with it medically because he felt surgery was too risky." This is consistent with the realistic risk calculus of neurosurgery in the 1970s and 1980s, when transsphenoidal microsurgery was evolving rapidly but carried non-trivial morbidity.

Why Surgical Risk Was a Reasonable Concern in His Era

Transsphenoidal adenomectomy today carries a major complication rate below 2 percent at experienced centers, with surgical remission rates of 80 to 85 percent for microadenomas and 40 to 60 percent for macroadenomas 5. In the 1970s, outcomes were less predictable. Andre began his World Wrestling Federation career in 1973. At that time, octreotide, the first somatostatin analogue approved for acromegaly, had not yet been synthesized. It entered clinical use in Europe in the mid-1980s and received FDA approval for acromegaly in 1988 6.

His reported reluctance toward surgery, therefore, combined with the limited pharmacotherapy available to him, left him with essentially no effective medical intervention for most of his active career.

Inference vs. Documented Record

No medical records from Andre Roussimoff have been made public. Statements attributing specific diagnoses come from family accounts, wrestling colleagues, and biographers. The acromegaly diagnosis is widely cited in the medical and popular literature and is consistent with every clinical feature documented photographically and in interviews. HealthRX treats this diagnosis as historically supported but notes that no primary clinical documentation has been published.

The Cardiovascular Consequences of Untreated Acromegaly

Acromegalic cardiomyopathy is the leading cause of excess mortality in the condition. A 2018 meta-analysis of 16 studies covering 1,191 patients found that active acromegaly produces concentric biventricular hypertrophy, diastolic dysfunction, and, in advanced disease, systolic dysfunction and dilated cardiomyopathy 7.

Andre died on January 27, 1993, in Paris, from what his family described as heart failure. He was 46. Standardized mortality ratios (SMRs) in untreated acromegaly range from approximately 1.7 to 3.2 compared with age-matched controls 8, meaning his risk of premature death was roughly two to three times that of a person without the disease.

Cardiac Pathology Timeline in Acromegaly

The natural history follows three stages. In early disease, there is hyperdynamic circulation with high cardiac output. The middle stage brings concentric hypertrophy and diastolic dysfunction. Late-stage disease produces dilated cardiomyopathy with reduced ejection fraction, arrhythmia, and eventual heart failure 9. Andre's career spanned roughly two decades of continuous GH excess. By the early 1990s, he had almost certainly reached late-stage cardiac involvement.

His weight near the end of his career was reported at 520 pounds. Obesity itself strains the myocardium, but in acromegaly the hypertrophy is pathologically driven by GH and IGF-1 independent of body mass.

Sleep Apnea as a Compounding Factor

Acromegaly drives macroglossia, mandibular prognathism, and pharyngeal soft-tissue hypertrophy. These produce obstructive sleep apnea in 60 to 80 percent of patients with active disease 10. Untreated OSA accelerates right ventricular strain and pulmonary hypertension, further compounding the acromegalic cardiomyopathy. No records of polysomnography for Andre exist, but the anatomical substrate for severe OSA was visibly present.

Medications Available During Andre's Lifetime and What He Reportedly Used

Bromocriptine: The First Available Option

Before octreotide, bromocriptine (a dopamine agonist) was the only pharmacological option for GH-secreting tumors. Bromocriptine reduces GH levels in roughly 10 to 20 percent of acromegaly patients, achieving biochemical normalization in only about 10 percent 11. It also causes significant gastrointestinal side effects and orthostatic hypotension, which would have been problematic for a professional athlete performing nightly. No public account documents Andre taking bromocriptine.

Octreotide: Too Late for Most of His Career

Sandostatin (octreotide) received FDA approval for acromegaly on August 30, 1988 6. At that point Andre was 42 years old and had been wrestling professionally for approximately 19 years with untreated disease. Octreotide as a subcutaneous injection three times daily was the 1988 formulation. The long-acting release version, octreotide LAR (Sandostatin LAR Depot), was not approved until 1998, five years after Andre's death 12.

Whether Andre received octreotide in the final years of his life is not documented in any public record. His health visibly declined from 1988 onward, suggesting that even if he had access to the drug, it was not producing biochemical control.

Radiation Therapy

Conventional pituitary radiotherapy was available throughout Andre's career. It achieves biochemical remission in 40 to 60 percent of patients but over a 5 to 15-year latency period, during which GH excess continues 13. It also carries a high rate of hypopituitarism (60 to 80 percent at 10 years) and a small but real risk of secondary malignancy. It would not have provided the rapid GH normalization needed to prevent cardiac progression in his case.

What Modern Acromegaly Treatment Would Offer Today

A patient presenting today with Andre's clinical profile, a macroadenoma, very high GH and IGF-1 levels, longstanding disease, and significant cardiovascular comorbidity, would follow a structured protocol based on the 2014 Endocrine Society Clinical Practice Guideline on Acromegaly 3.

Step 1: Transsphenoidal Surgery as First-Line Treatment

Surgery remains the first-line treatment for most pituitary adenomas causing acromegaly. At high-volume centers performing more than 50 pituitary surgeries per year, remission rates for macroadenomas have improved to 50 to 60 percent, with a perioperative mortality below 0.5 percent 5. Even incomplete resection significantly debulks the tumor and improves the response to subsequent medical therapy.

Step 2: Somatostatin Analogues for Residual Disease

For patients with persistent GH and IGF-1 elevation after surgery, somatostatin analogues are the pharmacological backbone. Octreotide LAR 20 to 30 mg intramuscularly every 28 days achieves biochemical control (IGF-1 normalization) in approximately 25 to 35 percent of unselected patients 14. Lanreotide autogel 90 to 120 mg subcutaneously every 28 days shows comparable efficacy; the PRIMARYS trial (N=90) demonstrated IGF-1 normalization in 41.8 percent of patients with lanreotide 120 mg as primary treatment at 48 weeks 15.

The Endocrine Society guideline recommends titrating to the lowest dose achieving IGF-1 normalization. Target biochemistry: IGF-1 within the age-adjusted and sex-adjusted normal range and a fasting GH <1 ng/mL 3.

Step 3: Pegvisomant for Resistant Disease

Pegvisomant (Somavert), a GH-receptor antagonist, normalizes IGF-1 in 63 to 97 percent of patients with somatostatin-analogue-resistant acromegaly 16. It does not reduce tumor size and carries a small risk of transaminase elevation, requiring liver monitoring. For a patient like Andre, with decades of IGF-1 excess driving end-organ damage, pegvisomant would be the drug most likely to normalize IGF-1 quickly regardless of somatostatin-receptor expression on the tumor.

Pasireotide: A Newer Option

Pasireotide LAR (Signifor LAR), a multireceptor somatostatin analogue, binds somatostatin receptor subtypes 1, 2, 3, and 5. The PAOLA trial (N=198) showed IGF-1 normalization in 48.3 percent of patients at 24 weeks compared to 26.5 percent with octreotide LAR (P<0.0001) 17. Its main drawback is hyperglycemia, occurring in 57 percent of patients, due to inhibition of insulin secretion.

The Question of Whether Andre's Life Could Have Been Prolonged

This is a reasonable clinical question, not speculation.

Biochemical control of acromegaly reduces the SMR back toward 1.0 (the general-population baseline). A 2017 systematic review of 16 cohort studies found that patients achieving normal IGF-1 had an SMR of 1.06, not statistically different from the general population 18. Patients with persistently elevated IGF-1 retained an SMR above 2.0.

Andre's cardiac disease was likely advanced by the late 1980s. Even if he had started octreotide at approval in 1988, the acromegalic cardiomyopathy present after two decades of excess may not have fully reversed. Established myocardial fibrosis does not regress completely with GH normalization 7. Partial regression of hypertrophy is documented, but the window for meaningful cardiac recovery narrowed significantly after his 40th birthday.

Surgery in 1973, at the start of his WWF career, would have given him the best chance of a normal lifespan. That was technically feasible then, though with higher operative risk than today.

Acromegaly Screening and Modern Diagnosis

The diagnostic workup for suspected acromegaly begins with a serum IGF-1 level corrected for age and sex. If elevated, a glucose tolerance test (OGTT) measuring GH suppression confirms the diagnosis: a GH nadir <1 ng/mL after 75 g oral glucose essentially excludes acromegaly 3. MRI of the pituitary with gadolinium contrast then identifies tumor size, location, and cavernous sinus invasion.

A person with Andre's visible features presenting to a modern endocrinologist would have this workup completed within days. The average time to diagnosis in current practice has shortened to approximately 4.5 years from symptom onset in high-income countries 2, still too long, but dramatically better than in the 1960s or 1970s when no effective biochemical screening was routine.

Cardiovascular Monitoring Protocol in Active Acromegaly

Current guidelines recommend echocardiography at diagnosis and every 1 to 2 years in active disease 3. Colonoscopy is recommended at diagnosis and every 3 to 5 years given the increased colorectal polyp risk. Blood pressure, fasting glucose, and HbA1c monitoring are standard at every visit. Sleep study referral is appropriate when OSA symptoms are present or when the anatomical substrate makes it probable.

Andre's case illustrates every complication category: cardiovascular, metabolic, musculoskeletal, and airway. A modern multidisciplinary team would address each systematically.

The Legacy of Andre's Case in Medical Education

Acromegaly textbooks routinely use Andre the Giant as a case study because his condition was visible, documented photographically across 30 years, and untreated. His progressive facial coarsening, hand enlargement, and final weight gain offer a natural history record rarely available in modern practice, where treatment is initiated far earlier.

His case also illustrates the psychological and occupational barriers to treatment. His condition was simultaneously the source of his professional identity and his greatest medical threat. A wrestler known globally as "The Giant" faced a specific personal cost in accepting a diagnosis that, if treated, might have reduced the very physical characteristics that defined his career.

That tension between professional identity and medical necessity is not unique to Andre. Endocrinologists treating acromegaly regularly encounter patients who delay treatment for occupational, social, or psychological reasons. The Endocrine Society guideline notes that "patient values and preferences should be incorporated into shared decision-making" 3, acknowledging that biochemical targets must be pursued alongside quality-of-life considerations.

Andre reportedly told friends in the early 1990s that he was "at peace" with his condition and its consequences. No journalist has produced a primary source for that specific quote. It is repeated frequently in wrestling histories and should be treated as oral tradition rather than documented fact.